ClinicalTrials.gg

Program

TQB6411

A development code. Also written as “TQB6411 Injection”, “TQB6411 for Injection” and “TQB6411 injection”.

In Sino Biopharmaceutical's pipeline, EGFR/c-Met ADC. Its studies are mostly in Esophageal Neoplasms · Lung Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jan 16, 20263 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical33 open or runningphase 2since Jan 16, 2026Jun 20, 2025Feb 2027phase 2 · NCT07367516
  • Named in Sino Biopharmaceutical’s own pipeline as TQB6411, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2025First study: phase 1 study in Advanced Malignant TumorsFirst studyNCT07043751 · 216 planned · China
  2. Jan 16, 20262 phase 2 studiesPhase 2 reachedNCT07367529, NCT07367516

Ahead

  1. Feb 2027Primary completion: phase 2 study in Esophageal NeoplasmsNCT07367516
  2. Dec 2027Primary completion: phase 1 study in Advanced Malignant TumorsNCT07043751
  3. Dec 2028Primary completion: phase 2 study in Advanced Lung CancerNCT07367529

TargetBeta

“EGFR/c-Met ADC”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07367516Esophageal Neoplasms · China2RecruitingFeb 2027105
NCT07367529Advanced Lung Cancer · China2RecruitingDec 2028465
NCT07043751Advanced Malignant Tumors · China1RecruitingDec 2027216

How it is read

Names in the registry

  • “TQB6411 Injection”, 1 entry
  • “TQB6411 for Injection”, 1 entry
  • “TQB6411 injection”, 1 entry

Codes read as this program: TQB6411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.